Trials / Approved For Marketing
Approved For MarketingNCT05906706
Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid
An Open-Label, Expanded Access Program of Dupilumab in Adult Patients With Bullous Pemphigoid
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The objective of the program is to provide patients with Bullous Pemphigoid (BP), that participated in the R668-BP-1902 (NCT04206553) phase 2/3 study, dupilumab treatment and evaluate the long-term safety of dupilumab.
Detailed description
Expanded Access requests are only being considered in response to intermediate size patient population applications. Availability will depend on location.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dupilumab | Subcutaneous (SC) administration |
Timeline
- First posted
- 2023-06-18
- Last updated
- 2025-07-03
Source: ClinicalTrials.gov record NCT05906706. Inclusion in this directory is not an endorsement.